Tripping on nothing: the placebo effect and psychedelic drugs


Tuesday, 07 April, 2020

Tripping on nothing: the placebo effect and psychedelic drugs

New research from McGill University suggests that, in the right context, some people may experience psychedelic-like effects from placebos alone. Their study, published in the journal Psychopharmacology, reports what are claimed to be some of the strongest placebo effects on consciousness in the literature relating to psychedelic drugs.

Participants, who were expecting to take part in a study of the effects of drugs on creativity, spent four hours together in a room that had been set up to resemble a psychedelic party, with paintings, coloured lights and a DJ. To make the context seem credible and hide the deception, the study also involved 10 research assistants in white lab coats, psychiatrists and a security guard.

The 33 participants had been told they were being given a drug which resembled the active ingredient in psychedelic mushrooms and that they would experience changes in consciousness over the 4-hour period. In reality, everyone consumed a placebo. Among the participants were several actors who had been trained to slowly act out the effects of the ostensible drug, which the researchers thought would help convince the participants that everyone had consumed a psychedelic drug.

When asked near the end of the study, 61% of the participants reported some effect of the drug, ranging from mild changes to effects resembling taking a moderate or high dose of an actual drug. Several participants stated that they saw the paintings on the walls “move” or “reshape” themselves. Others described themselves as feeling “heavy… as if gravity [had] a stronger hold”, and one had a “come down” before another “wave” hit her. Several participants reported being certain that they had taken a psychedelic drug.

“These results may help explain ‘contact highs’ in which people experience the effects of a drug simply by being around others who have consumed it,” said Samuel Veissière, who supervised the study. “More generally, our study helps shed light on the ‘placebo boosting’ component inherent in all medical and therapeutic intervention, and the social influences that modulate these enhancing effects. Placebo effects may have been underestimated in psychedelic studies. The current trend towards ‘micro-dosing’ (consuming tiny amounts of psychedelic drugs to improve creativity), for example, may have a strong placebo component due to widespread cultural expectations that frame the response.”

“The study reinforces the power of context in psychedelic settings,” added lead author Jay Olson. “With the recent re-emergence of psychedelic therapy for disorders such as depression and anxiety, clinicians may be able to leverage these contextual factors to obtain similar therapeutic experiences from lower doses, which would further improve the safety of the drugs.”

Image credit: ©stock.adobe.com/au/René Sputh

Please follow us and share on Twitter and Facebook. You can also subscribe for FREE to our weekly newsletters and bimonthly magazine.

Related News

Stem cell experiments conducted in space

Scientists are one step closer to manufacturing stem cells in space — which could speed up...

Plug-and-play test evaluates T cell immunotherapy effectiveness

The plug-and-play test enables real-time monitoring of T cells that have been engineered to fight...

Common heart medicine may be causing depression

Beta blockers are unlikely to be needed for heart attack patients who have a normal pumping...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd